Adagene Inc
12
4
6
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
8.3%
1 terminated/withdrawn out of 12 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Role: collaborator
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
Role: lead
Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
Role: lead
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Role: lead
Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
Role: collaborator
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
Role: collaborator
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
Role: collaborator
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
Role: lead
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Role: lead
Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Role: lead
A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC
Role: collaborator
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
Role: lead
All 12 trials loaded